Thiosemicarbazones have been demonstrated to inhibit the expression and activation of the ErbB family of receptors in response to EGF in pancreatic carcinoma cells in vitro and in vivo (Kovacevic et al., 2016; Menezes et al., 2017). This evidence concerns the gene EGFR and exocrine pancreatic carcinoma.